Research Frontiers' Losses Widen Amid Rising Costs, Declining Revenue

TL;DR

**REFR is bleeding cash and revenue is shrinking, making it a risky bet unless their SPD tech finally hits big.**

AI Summary

RESEARCH FRONTIERS INC (REFR) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $1,280,021, a substantial rise from $703,442 in the prior year. This was primarily driven by a 22.3% decrease in fee income to $1,049,125 from $1,157,380, coupled with a 23.1% surge in total expenses to $2,407,750 from $1,974,969. Operating expenses alone climbed to $1,934,041 from $1,565,152, with notable increases in employee compensation, professional fees, directors' fees, and marketing. Research and development expenses also rose to $473,709 from $409,817. The company's cash and cash equivalents decreased significantly to $1,130,390 as of September 30, 2025, from $1,994,186 at December 31, 2024, and working capital declined to approximately $1.4 million. Despite these losses, REFR expects to have sufficient working capital for at least 12 months from the financial statement issuance date, relying on future equity issuances or commercialization of its SPD technology by licensees.

Why It Matters

This widening net loss and declining revenue for Research Frontiers (REFR) signals increased financial pressure, which could impact its ability to fund ongoing research and development crucial for its SPD technology. For investors, the substantial decrease in cash and working capital, alongside recurring losses, raises concerns about long-term viability and potential dilution from future equity issuances. Employees might face uncertainty if the company struggles to secure additional funding or commercialize its technology. Customers and the broader market for smart glass technology could see slower innovation or reduced product availability if REFR's financial health deteriorates, potentially impacting competitive dynamics in the specialized light-control film sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,280,021 for the nine months ended September 30, 2025, a significant increase from $703,442 in the prior year, and an accumulated deficit of approximately $126.9 million. Cash and cash equivalents decreased to $1,130,390 from $1,994,186, indicating a rapid burn rate, and the company explicitly states it may need to seek additional funding through future equity issuances, which could dilute existing shareholders.

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding REFR stock given the accelerating losses, declining cash reserves, and the stated need for potential future equity financing. Monitor closely for any significant commercialization breakthroughs from their 40+ licensees that could reverse the negative financial trends, but assume continued operational losses in the near term.

Financial Highlights

debt To Equity

N/A

revenue

$1,049,125

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,280,021

eps

N/A

gross Margin

N/A

cash Position

$1,130,390

revenue Growth

-22.3%

Revenue Breakdown

Key Numbers

• $1,280,021 — Net loss for nine months ended Sep 30, 2025 (Increased from $703,442 in 2024)
• $1,049,125 — Fee income for nine months ended Sep 30, 2025 (Decreased from $1,157,380 in 2024)
• $2,407,750 — Total expenses for nine months ended Sep 30, 2025 (Increased from $1,974,969 in 2024)
• $1,130,390 — Cash and cash equivalents as of Sep 30, 2025 (Decreased from $1,994,186 at Dec 31, 2024)
• $1.4 million — Working capital as of Sep 30, 2025 (Indicates liquidity position)
• $126.9 million — Accumulated deficit as of Sep 30, 2025 (Reflects historical losses)
• 33,648,221 — Common shares outstanding as of Nov 6, 2025 (Stable share count compared to Sep 30, 2025)
• 78% — Revenue from outside the United States for nine months ended Sep 30, 2025 (Increased from 59% in 2024, showing international reliance)

Key Players & Entities

• RESEARCH FRONTIERS INCORPORATED (company) — Registrant
• REFR (company) — Trading Symbol
• NASDAQ Stock Market (regulator) — Exchange where Common Stock is registered
• Chief Executive Officer (person) — Company's Chief Operating Decision Maker
• Chief Financial Officer (person) — Acting Chief Financial Officer
• Audit Committee (company) — Reviews consolidated operating results quarterly
• U.S. generally accepted accounting principles (regulator) — Accounting standards followed
• ASC 606 (regulator) — Revenue recognition standard

FAQ

Risk Factors

• Deteriorating Financial Performance [high — financial]: The company reported a net loss of $1,280,021 for the nine months ended September 30, 2025, a significant increase from $703,442 in the prior year. This was driven by a 22.3% decrease in fee income and a 23.1% surge in total expenses.
• Declining Liquidity [high — financial]: Cash and cash equivalents decreased substantially to $1,130,390 as of September 30, 2025, from $1,994,186 at December 31, 2024. Working capital also declined to approximately $1.4 million.
• Reliance on Future Financing and Commercialization [medium — operational]: The company expects to have sufficient working capital for at least 12 months, but this relies on future equity issuances or successful commercialization of its SPD technology by licensees, indicating a dependence on external factors.
• Increasing Operating Expenses [medium — operational]: Total expenses increased by 23.1% to $2,407,750, with operating expenses rising to $1,934,041. Notable increases were seen in employee compensation, professional fees, directors' fees, and marketing.
• Rising Research and Development Costs [medium — operational]: Research and development expenses increased to $473,709 from $409,817, indicating higher investment in product development.
• International Revenue Dependence [medium — market]: Revenue from outside the United States accounted for 78% of total revenue for the nine months ended September 30, 2025, up from 59% in the prior year, highlighting significant exposure to international markets and currency fluctuations.

Industry Context

Research Frontiers Inc. operates in the specialized field of light-control technology, primarily through its SPD technology. The industry is characterized by innovation and the need for significant R&D investment. Success often hinges on successful licensing agreements and the commercial adoption of patented technologies by manufacturers in various sectors, such as automotive and aerospace.

Regulatory Implications

As a technology licensing company, Research Frontiers Inc. is subject to intellectual property laws and regulations governing patent enforcement and licensing agreements. Compliance with international trade regulations may also be relevant given its significant international revenue.

What Investors Should Do

1. Monitor R&D spending and progress on SPD technology commercialization.
2. Evaluate the company's ability to secure future equity financing.
3. Assess the impact of international market performance and currency fluctuations.

Glossary

SPD technology

Suspended Particle Device technology, likely related to display or light-filtering applications. (This is the company's core technology that it relies on for future revenue through licensing.)

Working capital

The difference between a company's current assets and current liabilities, indicating its short-term financial health and ability to meet obligations. (A decline in working capital to $1.4 million signals reduced short-term liquidity for REFR.)

Accumulated deficit

The total net losses of a company since its inception, representing the cumulative negative earnings. (REFR has an accumulated deficit of $126.9 million, underscoring its history of unprofitability.)

Year-Over-Year Comparison

Research Frontiers Inc. has experienced a significant deterioration in its financial performance compared to the prior year's comparable period. Net losses have nearly doubled, driven by a substantial decrease in fee income and a sharp increase in total expenses, particularly operating costs. While revenue from outside the U.S. has become a larger proportion of the total, the overall revenue has declined. The company's liquidity has also weakened, with a notable drop in cash and cash equivalents and working capital, raising concerns about its short-term financial stability.

Key Financial Figures

• $0.0001 — nge on Which Registered Common Stock, $0.0001 Par Value The NASDAQ Stock Market S

Filing Documents

• form10-q.htm (10-Q) — 419KB
• ex31-1.htm (EX-31.1) — 15KB
• ex32-1.htm (EX-32.1) — 8KB
• 0001493152-25-021062.txt ( ) — 2501KB
• refr-20250930.xsd (EX-101.SCH) — 23KB
• refr-20250930_cal.xml (EX-101.CAL) — 41KB
• refr-20250930_def.xml (EX-101.DEF) — 58KB
• refr-20250930_lab.xml (EX-101.LAB) — 185KB
• refr-20250930_pre.xml (EX-101.PRE) — 138KB
• form10-q_htm.xml (XML) — 279KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 14-16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 17

Controls and Procedures

Item 4. Controls and Procedures 17

- OTHER INFORMATION

PART II - OTHER INFORMATION

Exhibits

Item 6. Exhibits 18

SIGNATURES

SIGNATURES 19 2 RESEARCH FRONTIERS INCORPORATED Condensed Consolidated Balance Sheets September 30, 2025 (Unaudited) December 31, 2024 (See Note 1) Assets Current assets: Cash and cash equivalents $ 1,130,390 $ 1,994,186 Royalties receivable, net of reserves of $ 1,354,850 in 2025 and $ 1,253,450 in 2024, respectively 371,878 658,213 Prepaid expenses and other current assets 112,604 93,490 Total current assets 1,614,872 2,745,889 Fixed assets, net 6,355 15,052 Operating lease ROU assets 1,092,033 1,222,640 Deposits and other assets 56,066 56,066 Total assets $ 2,769,326 $ 4,039,647 Liabilities and Shareholders' Equity Current liabilities: Current portion of operating lease liability $ 141,894 $ 129,875 Accounts payable 29,137 85,825 Accrued expenses 35,721 53,327 Deferred revenue 5,336 - Total current liabilities 212,088 269,027 Operating lease liability, net of current portion 1,057,720 1,166,285 Total liabilities 1,269,808 1,435,312 Shareholders' equity: Common stock, par value $ 0.0001 per share; authorized 100,000,000 shares, issued and outstanding 33,648,221 in 2025 and 2024, respectively 3,365 3,365 Additional paid-in capital 128,352,397 128,177,193 Accumulated deficit ( 126,856,244 ) ( 125,576,223 ) Total shareholders' equity 1,499,518 2,604,335 Total liabilities and shareholders' equity $ 2,769,326 $ 4,039,647 See accompanying notes to condensed consolidated financial statements. 3 RESEARCH FRONTIERS INCORPORATED Condensed Consolidated Statements of Operations (Unaudited) 2025 2024 2025 2024 Nine months ended September 30, Three months ended September 30, 2025 2024 2025 2024 Fee income $ 1,049,125 $ 1,157,380 $ 359,444 $ 354,408 Operating expenses 1,934,041 1,565,152 521,642 454,866 Research and development 473,709 409,817 141,746 131,246 Total expenses 2,407,750 1,974,969 663,388 586,112 Operating loss ( 1,35

View Full Filing

View this 10-Q filing on SEC EDGAR